AG Mednet Expands Leadership to Power Judi’s Next Phase of Growth
AG Mednet, known for clinical trial process management, is experiencing strong momentum as its Judi platform gains broad adoption. Judi now supports more than 2,000 clinical trials and works alongside 640 drug and device sponsors and 90 Contract Research Organizations (CROs) worldwide.
Rapid Growth of the Judi Platform
Growing demand for Judi has prompted AG Mednet to deepen its leadership bench. The company has appointed Catherine Tyner as Head of Clinical Strategy and Jamie Russo as Head of Product. These hires are designed to help the team scale thoughtfully while continuing to deliver the quality, reliability, and innovation partners expect as usage of the Judi platform accelerates.
Catherine Tyner’s Mandate
Catherine Tyner brings 27 years of clinical research experience, with a focus on Oversight Group Management for Clinical Endpoint Committees and other critical operations. Her leadership career includes roles at Quintiles, Novella Clinical, and Covance. She has led oversight departments supporting more than 500 clinical trials, including complex, multi-therapeutic studies. As Head of Clinical Strategy, she will concentrate on optimizing clinical processes to increase value for both new and existing sponsors and CROs.
Tyner on Joining AG Mednet
Tyner shared her perspective: “I’m thrilled to be joining AG Mednet at such a pivotal time. The Judi platform is leading the way in clinical process management, showcasing excellence in data monitoring and adjudication best practices. I look forward to driving further progress in this space and contributing to Judi’s growth and adoption.”
Focus on Product Innovation
Appointing Jamie Russo as Head of Product underscores AG Mednet’s commitment to advancing its product strategy. Russo brings more than a decade of experience spanning healthcare and technology, including roles at PathAI and Massachusetts General Hospital. Her work centers on aligning healthcare technology with the practical, evolving needs of clinical research teams.
Russo’s Vision
In her new role, Russo plans to expand AI-enabled capabilities across the Judi platform. She recognizes AG Mednet’s record of helping clinical trials run efficiently and sees a clear path for future growth. “I’m eager to help propel the innovation that has defined AG Mednet,” she said.
A Commitment to Quality and Precision
AG Mednet’s CEO, Abraham Gutman, emphasized that the company will continue to meet rising demand for Judi with a focus on quality and precision. The leadership updates reflect AG Mednet’s dedication to consistent, incremental innovation across the clinical development lifecycle.
Embedding Efficiency in Clinical Trials
As Judi evolves, AG Mednet is strengthening collaboration among sponsors, CROs, and oversight groups. The company’s focus remains on improving the efficiency of event adjudication, eligibility determination, and remote monitoring so study teams can move faster while maintaining rigor.
Global Impact of the Judi Platform
Adoption of Judi has driven broader collaboration across the industry. Over the past year alone, AG Mednet added more than 100 unique trial sponsors. The platform now supports studies across 20 therapeutic areas, demonstrating its adaptability to many trial designs and operational needs.
Future Directions for AG Mednet
Looking ahead, AG Mednet plans to carry this momentum into the new year. The focus remains on advancing clinical research with innovative AI solutions and on building collaborations that help bring therapies to patients more efficiently worldwide.
About AG Mednet
AG Mednet streamlines the clinical trial process with its award-winning Judi platform, which simplifies essential workflows, improves communication, and helps accelerate the development of life-saving therapies. With broad adoption among global biopharmaceutical sponsors and leading CROs, Judi supports transparency and efficiency across clinical processes, from endpoint adjudication to data safety monitoring.
Frequently Asked Questions
What is Judi, and how widely is it used?
Judi is AG Mednet’s platform for clinical trial process management. It is in use across more than 2,000 clinical trials with participation from 640 drug and device sponsors and 90 CROs, supporting activities such as event adjudication, eligibility determination, remote monitoring, and data safety monitoring.
Who are the new leaders, and what will they do?
Catherine Tyner has joined as Head of Clinical Strategy, bringing 27 years of clinical research experience and a background in oversight for Clinical Endpoint Committees. Jamie Russo is the new Head of Product, with more than ten years in healthcare and technology. Together, they will optimize clinical processes and guide the platform’s product strategy, including AI-enabled capabilities.
Why is AG Mednet expanding its leadership now?
Demand for Judi is surging. Expanding the leadership team helps AG Mednet scale responsibly, maintain high standards for quality and precision, and continue delivering innovation as more sponsors and CROs adopt the platform.
What impact is Judi having globally?
Judi has supported wide industry collaboration, including onboarding more than 100 unique trial sponsors in the past year. The platform is used across 20 therapeutic areas, reflecting its flexibility for different study designs and operational needs.
How will AI shape the next phase of Judi?
Under Jamie Russo’s product leadership, AG Mednet plans to extend AI-enabled solutions across Judi. The goal is to help clinical trials run efficiently while supporting high standards in data monitoring and adjudication—advancing the company’s ongoing commitment to innovation.
